A Phase II Study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours.
Authors
Fazio, NBuzzoni, R
Baudin, E
Antonuzzo, L
Hubner, Richard A
Lahner, H
De Herder, W
Raderer, M
Teulé, A
Capdevila, J
Libutti, S
Kulke, M
Shah, M
Dey, D
Turri, S
Aimone, P
Massacesi, C
Verslype, C
Affiliation
European Institute of Oncology, Milan, ItalyIssue Date
2016-02
Metadata
Show full item recordAbstract
This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436).Citation
A Phase II Study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. 2016, 36 (2):713-9 Anticancer ResJournal
Anticancer ResearchPubMed ID
26851029Type
ArticleLanguage
enISSN
1791-7530Collections
Related articles
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
- Authors: Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC
- Issue date: 2018 Jul
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
- Authors: Vandamme T, Beyens M, de Beeck KO, Dogan F, van Koetsveld PM, Pauwels P, Mortier G, Vangestel C, de Herder W, Van Camp G, Peeters M, Hofland LJ
- Issue date: 2016 Mar 15
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
- Authors: Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC
- Issue date: 2017 Jun
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
- Authors: Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP
- Issue date: 2016 Sep
- A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
- Authors: Lang F, Wunderle L, Badura S, Schleyer E, Brüggemann M, Serve H, Schnittger S, Gökbuget N, Pfeifer H, Wagner S, Ashelford K, Bug G, Ottmann OG
- Issue date: 2020 Sep 29